Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

“Authorized” Generics Fight Moves To Capitol Hill, FTC

This article was originally published in The Pink Sheet Daily

Executive Summary

Mylan plans to meet with Hill staffers, members of Congress to lay the groundwork for legislation against “authorized” generic deals. The company is leading efforts of generic firms who are trying to persuade FTC that authorized generics do not save consumers money and result in fewer patent challenges.

You may also be interested in...



FTC Should Study Competitive Impact Of "Authorized" Generics, Senators Say

Bipartisan group of senators requests investigation of the short- and long-term competitive impacts of "authorized" generics. Formal study request and remarks by one of the commissioners suggest the generic industry's arguments against the practice are gaining traction on Capitol Hill and at FTC.

FTC Should Study Competitive Impact Of "Authorized" Generics, Senators Say

Bipartisan group of senators requests investigation of the short- and long-term competitive impacts of "authorized" generics. Formal study request and remarks by one of the commissioners suggest the generic industry's arguments against the practice are gaining traction on Capitol Hill and at FTC.

Congress, Not Court, Is Place To Change "Authorized" Generic Policy, Judge Says

Congress is a better venue for changing FDA's regulation of "authorized" or brand generics, a D.C. Circuit Court of Appeals judge suggests. Teva faces skepticism during oral arguments in its challenge of the agency's refusal to block authorized generics during an ANDA first-filer's 180-day exclusivity.

Related Content

Topics

UsernamePublicRestriction

Register

PS060306

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel